Compare Stocks: SONX, PAVM, LFWD, and FEMY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FEMY Femasys	$1.75 -12.5%	$2.58	$1.71 ▼ $22.20	$16.75M	-2.16	90,444 shs	66,525 shs
LFWD Lifeward	$6.40 -1.4%	$7.11	$4.14 ▼ $9.61	$18.38M	0.47	5,763 shs	1,740 shs
PAVM PAVmed	$2.69 -3.6%	$4.33	$2.58 ▼ $28.44	$22.31M	0.69	27,949 shs	8,623 shs
SONX Sonendo	$1.28	$1.07	$0.02 ▼ $1.90	$6.11M	1.86	1,247 shs	N/A

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FEMY Femasys	0.00%	-2.44%	-28.06%	-42.36%	-83.67%
LFWD Lifeward	0.00%	+10.94%	-10.25%	-18.36%	-26.86%
PAVM PAVmed	0.00%	-2.79%	-33.25%	-49.27%	-80.97%
SONX Sonendo	0.00%	+50.59%	-1.54%	+113.33%	+220.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FEMY Femasys	$1.75 -12.5%	$2.58	$1.71 ▼ $22.20	$16.75M	-2.16	90,444 shs	66,525 shs
LFWD Lifeward	$6.40 -1.4%	$7.11	$4.14 ▼ $9.61	$18.38M	0.47	5,763 shs	1,740 shs
PAVM PAVmed	$2.69 -3.6%	$4.33	$2.58 ▼ $28.44	$22.31M	0.69	27,949 shs	8,623 shs
SONX Sonendo	$1.28	$1.07	$0.02 ▼ $1.90	$6.11M	1.86	1,247 shs	N/A

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FEMY Femasys	0.00%	-2.44%	-28.06%	-42.36%	-83.67%
LFWD Lifeward	0.00%	+10.94%	-10.25%	-18.36%	-26.86%
PAVM PAVmed	0.00%	-2.79%	-33.25%	-49.27%	-80.97%
SONX Sonendo	0.00%	+50.59%	-1.54%	+113.33%	+220.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FEMY Femasys	2.50	Moderate Buy	$50.00	2,757.14% Upside
LFWD Lifeward	2.25	Hold	$10.00	56.25% Upside
PAVM PAVmed	2.00	Hold	$56.00	1,981.78% Upside
SONX Sonendo	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SONX, PAVM, LFWD, and FEMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/24/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	LFWD Lifeward	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	LFWD Lifeward	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/18/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	FEMY Femasys	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00
8/17/2026	FEMY Femasys	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	PAVM PAVmed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/14/2026	FEMY Femasys	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00
8/3/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FEMY Femasys	$2.30M	6.37	N/A	N/A	$2.01 per share	0.87
LFWD Lifeward	$22.03M	0.82	N/A	N/A	$5.52 per share	1.16
PAVM PAVmed	$70K	307.43	N/A	N/A	($2.42) per share	-1.11
SONX Sonendo	$44.40M	0.14	N/A	N/A	$89.42 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FEMY Femasys	-$18.63M	-$3.53	N/A	N/A	N/A	-534.36%	-225.97%	-74.68%	11/17/2026 (Estimated)
LFWD Lifeward	-$19.91M	-$16.82	N/A	N/A	N/A	-141.28%	-235.86%	-81.72%	11/13/2026 (Estimated)
PAVM PAVmed	$400K	-$16.05	N/A	N/A	N/A	-10,794.64%	-126.43%	-25.49%	11/12/2026 (Estimated)
SONX Sonendo	-$60.92M	-$71.12	N/A	N/A	N/A	-92.74%	-184.01%	-68.60%	11/11/2026 (Estimated)

Latest SONX, PAVM, LFWD, and FEMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/15/2026	Q2 2026	LFWD Lifeward	-$1.39	-$1.46	-$0.07	-$4.12	$6.53 million	$6.62 million
8/14/2026	Q2 2026	FEMY Femasys	-$1.31	-$1.33	-$0.02	-$1.33	$0.73 million	$0.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FEMY Femasys	N/A	N/A	N/A	N/A	N/A
LFWD Lifeward	N/A	N/A	N/A	N/A	N/A
PAVM PAVmed	N/A	N/A	N/A	N/A	N/A
SONX Sonendo	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FEMY Femasys	0.89	2.14	0.55
LFWD Lifeward	0.70	2.33	1.77
PAVM PAVmed	0.98	1.19	1.19
SONX Sonendo	0.55	1.82	1.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FEMY Femasys	65.27%
LFWD Lifeward	26.76%
PAVM PAVmed	19.93%
SONX Sonendo	28.68%

Insider Ownership

Company	Insider Ownership
FEMY Femasys	7.75%
LFWD Lifeward	1.10%
PAVM PAVmed	13.40%
SONX Sonendo	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FEMY Femasys	54	8.38 million	7.73 million	Not Optionable
LFWD Lifeward	81	2.83 million	2.80 million	Optionable
PAVM PAVmed	41	8.00 million	6.93 million	No Data
SONX Sonendo	250	4.78 million	393,000	Not Optionable

SONX, PAVM, LFWD, and FEMY Headlines

Recent News About These Companies

Sonendo Achieves Milestone of Two Million Patients Treated with the GentleWave® Procedure

September 21, 2026 | businesswire.com

Sonendo Announces Key Initiatives to Drive Business Towards Cashflow Break-Even

August 25, 2026 | businesswire.com

Sonendo, Inc. to Report Third Quarter 2024 Financial Results on November 12, 2024

June 26, 2026 | businesswire.com

Sonendo Stock Price, Quotes and Forecasts | OTC:SONX | Benzinga

April 8, 2026 | benzinga.com

Sonendo, Inc. on Path to Breakeven in the Second Half of 2026

March 16, 2026 | businesswire.com

Sonendo Strengthens Leadership Team With Promotion of John McGaugh to ...

August 22, 2025 | businesswire.com

Sonendo names John McGaugh COO

August 20, 2025 | msn.com

Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer

August 20, 2025 | businesswire.com

Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance

August 13, 2025 | businesswire.com

Sonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial Guidance

June 4, 2025 | businesswire.com

Sonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

March 26, 2025 | businesswire.com

Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024

November 11, 2024 | businesswire.com

Sonendo, Inc. (SONX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

November 5, 2024 | zacks.com

Sonendo Launches ProControlTM for the GentleWave® G4 System

October 23, 2024 | businesswire.com

Sonendo, Inc. Announces Preliminary Third Quarter 2024 Financial Results

October 10, 2024 | businesswire.com

BIOLASE files for Chapter 11, plans asset sale to Sonendo

October 3, 2024 | investing.com

Here's Why Sonendo (SONX) Is a Great 'Buy the Bottom' Stock Now

August 27, 2024 | zacks.com

Sonendo Inc.

August 17, 2024 | marketwatch.com

Sonendo, Inc. (SONX) Q2 2024 Earnings Call Transcript

August 10, 2024 | seekingalpha.com

Sonendo, Inc. (SONX) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2024 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SONX, PAVM, LFWD, and FEMY Company Descriptions

Femasys NASDAQ:FEMY

$1.75 -0.25 (-12.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.88 +0.13 (+7.60%)

As of 07:50 PM Eastern

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Lifeward NASDAQ:LFWD

$6.40 -0.09 (-1.39%)

Closing price 03:59 PM Eastern

Extended Trading

$6.42 +0.01 (+0.23%)

As of 07:30 PM Eastern

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

PAVmed NASDAQ:PAVM

$2.69 -0.10 (-3.58%)

Closing price 04:00 PM Eastern

Extended Trading

$2.71 +0.02 (+0.74%)

As of 05:09 PM Eastern

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Sonendo NYSE:SONX

$1.28 0.00 (0.00%)

As of 10/9/2026

Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment, a technology platform designed for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid EDTA that is used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software to enable an integrated digital office for dental practitioners. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. The company was incorporated in 2006 and is headquartered in Laguna Hills, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SONX, PAVM, LFWD, and FEMY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SONX, PAVM, LFWD, and FEMY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SONX, PAVM, LFWD, and FEMY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SONX, PAVM, LFWD, and FEMY Company Descriptions

Femasys NASDAQ:FEMY

Lifeward NASDAQ:LFWD

PAVmed NASDAQ:PAVM

Sonendo NYSE:SONX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SONX, PAVM, LFWD, and FEMY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SONX, PAVM, LFWD, and FEMY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SONX, PAVM, LFWD, and FEMY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SONX, PAVM, LFWD, and FEMY Company Descriptions

Femasys NASDAQ:FEMY

Lifeward NASDAQ:LFWD

PAVmed NASDAQ:PAVM

Sonendo NYSE:SONX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools